Fig. 5.

Galectin-1 inhibition combined with vincristine results in increased cytotoxicity to ALL cells in vitro. a and c. Representative analysis of proliferation (left panels, cell numbers) and viability (right panels) of LAX56 (a) and LAX57 (c) treated for 72 h with PTX008 alone (top panels) or PTX008 plus vincristine (bottom panels) in the presence of OP9 stromal support. Error bars, standard deviation (*p<0.05, 95% CI, 1-way ANOVA). b and d Summary fold difference LAX56 (b) and LAX57 (d). Cell number and viability was normalized to DMSO or vincristine only control for 3 replicate experiments with 3 replicate samples. Error bars represent standard error of mean (*, p<0.05; **, p<0.01; ***, p<0.001, two-tailed t-test). e Cell counts (left panel) and viability (right panel) of LAX56 in combination treatment for 72 h with a fixed amount of 10 μM PTX008 (− 1 and − 2: drug from different sources) and the indicated concentration of vincristine in the presence of mitotically inactivated (mitomycin C-treated) OP9 stroma. Error bars, SD. One experiment, triplicate wells (*, p<0.05; ***, p<0.001, ****, p<0.0001, compared to vincristine only or DMSO [0 nM vincristine]). Two way ANOVA, Dunnett’s multiple comparison test